News Releases

  • Email
  • Print
  • Share
  • Text
Highlight Glossary Terms

News tagged ‘OvarianCancer’ clear

  • As part of Project Achilles, aimed at finding the "Achilles heel" of cancer, researchers from Dana-Farber Cancer Institute, Harvard and the Broad Institute of MIT examined cells from over 100 tumors, including 25 ovarian cancer tumors, finding promising new targets for genetic research.

Tags: BasicResearch, OvarianCancer, GynecologicCancers

  • On Sept. 6 at Boston City Hall Plaza, Dana-Farber/Brigham and Women's Cancer Center, along with a coalition of six organizations, launched a month-long campaign to promote ovarian cancer awareness. The group, known as OvarianCancerAwareness.org, is dedicated to educating the public about the subtle symptoms of ovarian cancer to promote early detection.

Tags: OvarianCancer

  • A novel pairing of two cancer drug types showed promising activity and had manageable toxicities, according to a first-of-its-kind clinical trial led by scientists at Dana-Farber Cancer Institute.

Tags: BreastCancer, OvarianCancer, GynecologicCancers

  • A new Dana-Farber Cancer Institute study suggests there is a direct connection between high-grade serous ovarian cancer (HGSOC) and fallopian tubes. The finding could aid in the development of better treatments for the cancer.

Tags: OvarianCancer, GynecologicCancers

  • New research shows patients with non-metastatic ovarian cancer live longer when chemotherapy is delivered into the abdomen instead of by standard intravenous infusion, yet only a minority of eligible patients are receiving it.

Tags: OvarianCancer

  • A "watch and wait" strategy reduces the need for unnecessary chemo in young girls, which can lead to secondary cancers and other health issues later in life.

Tags: ChildhoodCancer, OvarianCancer, PatientEducation

  • Researchers from the Susan F. Smith Center for Women’s Cancers at Dana-Farber report that for some women with recurrent ovarian cancer, a new drug combination has been found to stall the progression of the disease.

Tags: OvarianCancer, GynecologicCancers

  • Scientists from Brigham and Women's Hospital and Dana-Farber Cancer Institute and their colleagues have found a genetic marker that predicts which aggressive "triple negative" breast cancers and certain ovarian cancers will likely respond to platinum-based chemotherapies.

Tags: BasicResearch, BreastCancer, Genomics, OvarianCancer, GynecologicCancers

  • A widely used diabetes drug dramatically boosted the potency of platinum-based cancer drugs when administered together to a variety of cancer cell lines and to mice with tumors, scientists from Dana-Farber report.

Tags: LungCancer, OvarianCancer

  • Ursula Matulonis, MD, the director of the Gynecological Cancer Treatment Center in the Susan F. Smith Center for Women’s Cancers at Dana-Farber receives a $900,000 grant from the Ovarian Cancer Research Foundation (OCRF) to test new combinations of targeted drugs against the disease.

Tags: Grants, OvarianCancer, GynecologicCancers

Showing 11-20 of 23 items